News
LXEO
4.750
+1.06%
0.050
Lexeo Therapeutics Is Maintained at Overweight by JP Morgan
Dow Jones · 3d ago
Lexeo Therapeutics Price Target Cut to $9.00/Share From $12.00 by JP Morgan
Dow Jones · 3d ago
JP Morgan Maintains Overweight on Lexeo Therapeutics, Lowers Price Target to $9
Benzinga · 3d ago
Lexeo Therapeutics price target lowered to $9 from $12 at JPMorgan
TipRanks · 3d ago
Lexeo Therapeutics's LX2006 Has A Viable Regulatory Pathway And Timeline
Seeking Alpha · 6d ago
Weekly Report: what happened at LXEO last week (0615-0619)?
Weekly Report · 6d ago
Lexeo Therapeutics Reports Data For LX2006 Gene Therapy In Friedreich Ataxia, Pivotal SUNRISE-FA 2 Study On Track For 2026 Launch, Publishid In The JAMA Cardiology
Benzinga · 06/17 20:04
Lexeo says LX2006 Phase I/II Friedreich ataxia data show early efficacy in JAMA Cardiology publication
PUBT · 06/17 20:01
Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
Barchart · 06/17 15:01
BUZZ-U.S. STOCKS ON THE MOVE-Datadog, Terawulf
Reuters · 06/15 15:50
Why Is Lexeo Therapeutics Stock Gaining Monday?
Benzinga · 06/15 15:32
BUZZ-Lexeo rises as co sets late-stage trial plan for gene therapy in rare heart disease
Reuters · 06/15 14:11
Pre-Market Movers: BYAH, LXEO, ELTX Swing Big
NASDAQ · 06/15 13:12
Lexeo finalizes SUNRISE-FA 2 pivotal trial protocol, statistical analysis plan
TipRanks · 06/15 11:35
Lexeo Advances Pivotal LX2006 Trial for FA Cardiomyopathy
TipRanks · 06/15 11:31
Lexeo Therapeutics posts LX2006 regulatory update presentation for Friedreich ataxia treatment program
PUBT · 06/15 11:15
Lexeo Therapeutics releases corporate presentation on cardiac gene therapy platform for inherited heart disease
PUBT · 06/15 11:15
Lexeo Therapeutics Finalized SUNRISE-FA Pivotal Trial Protocol And Statistical Analysis Plan Intended To Provide Clinical Evidence To Support Submission FDA Application For Gene Therapy Candidate LX2006 Under The Accelerated Approval Pathway In 2028
Benzinga · 06/15 11:04
Lexeo finalizes SUNRISE-FA 2 pivotal trial design for LX2006 in Friedreich ataxia cardiomyopathy
PUBT · 06/15 11:01
LEXEO THERAPEUTICS ANNOUNCES REGULATORY UPDATE AND REGISTRATIONAL TRIAL DESIGN FOR LX2006 GENE THERAPY IN FRIEDREICH ATAXIA
Reuters · 06/15 11:00
More
Webull provides a variety of real-time LXEO stock news. You can receive the latest news about Lexeo Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About LXEO
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).